Johnson & Johnson (JNJ.US) submits regulatory application to FDA for antibody therapy for moderate to severe active ulcerative colitis
Sunday, Nov 24, 2024 4:10 am ET
1min read Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biologics License Application (sBLA) to the US FDA seeking approval of its anti-IL-23 antibody Tremfya (guselkumab) as a subcutaneous (SC) induction regimen for the treatment of adults with moderate to severe active ulcerative colitis (UC).
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.